Argos Therapeutics (ARGS) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
March 29, 2016 4:30 PM EDT- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 Â
- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 Following Data Reviews in June and December 2015 -Â
- Established Scientific Advisory Board in July 2015 Â
- Early stage RCC trial of AGS-003 Commenced at Roswell Park Cancer Institute in July 2015 -Â
- Conference Call and Webcast Today, March 29th, at 4:30 p.m. ET -
DURHAM, N.C., March 29, 2016 (GLOBE NEWSWIRE) --... More
